<DOC>
	<DOCNO>NCT02377713</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics KHK6640 , give single dose Japanese patient Mild Moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>A Single Dose Study KHK6640 Japanese Patients With Alzheimer 's Disease .</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients mild moderate Alzheimer 's Disease Body weight ≥ 40 kg &lt; 100 kg Clinical Dementia Rating ( CDR ) score 1 2 Mini Mental State Examination ( MMSE ) score ≥ 17 amd ≤ 26 Previous active treatment Alzheimer 's Disease immunotherapy investigational study Use another investigational drug within 4 month prior enrollment Subjects meet National Institute Neurological Disorders Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( NINDS/AIREN ) criteria vascular dementia Subjects history presence clinically significant seizure , brain trauma , transient ischemic attack , and/or cerebrovascular disease Subjects presence neurological condition could contribute cognitive impairment beyond cause subject 's Alzheimer 's Disease Subjects evidence infection , tumor , clinically significant lesion could indicate dementia diagnosis Alzheimer 's Disease</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>KHK6640</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Japanese</keyword>
	<keyword>single dose</keyword>
	<keyword>Alzheimer 's disease</keyword>
</DOC>